Treatment for Macular Edema following RVO | VABYSMO® (faricimab-svoa)

Skip To Main Content

*On average, people with CRVO gained 13 letters at 1 month after their first treatment while people with BRVO gained 11 letters at 1 month after their first treatment on an eye chart with VABYSMO, similar to aflibercept 2 mg. On average, people with CRVO and BRVO gained and maintained 17 letters over 6 months on an eye chart with VABYSMO, similar to aflibercept 2 mg. BRVO=branch retinal vein occlusion; CRVO=central retinal vein occlusion.

Why VABYSMO might be right for you

Improves vision quickly*

Icon - double-check

It’s the only FDA-approved treatment thought to block 2 causes of macular edema following RVO^†

Can help quickly dry excessive fluid that causes swelling in the back of the eye^‡

*On average, people with CRVO gained 13 letters at 1 month after their first treatment while people with BRVO gained 11 letters at 1 month after their first treatment on an eye chart with VABYSMO, similar to aflibercept 2 mg. On average, people with CRVO and BRVO gained and maintained 17 letters over 6 months on an eye chart with VABYSMO, similar to aflibercept 2 mg. BRVO=branch retinal vein occlusion; CRVO=central retinal vein occlusion.
^†VABYSMO is thought to block the VEGF and Ang-2 proteins. The benefit of blocking Ang-2 has yet to be established.
^‡In 2 clinical trials, VABYSMO was shown to help reduce excess damaging fluid in the eye, similar to aflibercept 2 mg.
Ang-2=angiopoietin-2; BRVO=branch retinal vein occlusion; CRVO=central retinal vein occlusion; VEGF=vascular endothelial growth factor.

^†VABYSMO is thought to block the VEGF and Ang-2 proteins. The benefit of blocking Ang-2 has yet to be established.
^‡In 2 clinical trials, VABYSMO was shown to help reduce excess damaging fluid in the eye, similar to aflibercept 2 mg.
Ang-2=angiopoietin-2; BRVO=branch retinal vein occlusion; CRVO=central retinal vein occlusion; VEGF=vascular endothelial growth factor.

What is VABYSMO?

Learn about the science behind how VABYSMO works

Treatment with VABYSMO

Explore clinical trial results and what to expect from treatment

See the difference

Financial support

Find out how you could save on your VABYSMO, even if you have no health insurance

Explore our options

NEXT: What is RVO?

What is VABYSMO?

VABYSMO (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with neovascular (wet) age‑related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).

Do not receive VABYSMO if you:

Have an infection in or around your eye.
Have active swelling around your eye that may include pain and redness.
Are allergic to VABYSMO or any of the ingredients in VABYSMO.

What is the most important information I should know about VABYSMO?

Injections like the one for VABYSMO can cause an eye infection (endophthalmitis), separation of layers of the retina (retinal detachment), or inflammation in the eye that can lead to vision loss. Call your healthcare provider right away if your eye becomes red, sensitive to light, or you have a change or loss of vision.
VABYSMO may cause a temporary increase in pressure in the eye (intraocular pressure), which occurs within 60 minutes after receiving the eye injection.
Although not common, VABYSMO patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes (thromboembolic events). In clinical studies for wet AMD during the first year, 7 out of 664 patients treated with VABYSMO reported such an event. In clinical studies for DME from baseline to week 100, 64 out of 1,262 patients treated with VABYSMO reported such an event. In clinical studies for RVO during 6 months, 7 out of 641 patients treated with VABYSMO reported such an event.
Severe inflammation of vessels in the retina has happened for patients treated with VABYSMO. Call your healthcare provider immediately if you experience a change in vision.

Before receiving VABYSMO, tell your healthcare provider about all of your medical conditions, including if you:

Are pregnant or plan to become pregnant. Based on how VABYSMO interacts with your body, there may be a potential risk to your unborn baby. You should use birth control before your first injection, during your treatment with VABYSMO, and for 3 months after your last dose of VABYSMO.
Are breastfeeding or plan to breastfeed. It is not known if VABYSMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive VABYSMO.
Are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider about all the medicines you take.

What should I avoid while receiving VABYSMO?

Your vision may be impaired after receiving an eye injection or after an eye exam. Do not drive or use machinery until your vision has recovered sufficiently.

What are the most common side effects with VABYSMO?

The most common side effects with VABYSMO were cataract and blood on the white of the eye (conjunctival hemorrhage).
These are not all the possible side effects of VABYSMO.

Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.

Please see the VABYSMO full Prescribing Information for additional Important Safety Information.